Editorial Standards

Last updated: 2026

OptimizeForever covers medically sensitive subject matter — GLP-1 medications, peptide therapy, hormone health, and longevity science. Because decisions readers make based on this content can affect their health, we hold ourselves to a specific, disclosed editorial standard rather than asking readers to simply trust us.

Our Three-Tier Evidence Standard

Every health claim published on this site is classified into one of three evidence tiers, and the language we use reflects which tier it falls into:

Well-documented. Claims supported by multiple peer-reviewed studies, large randomized controlled trials, or established clinical consensus. We state these with corresponding confidence — language like “research consistently shows” or “well-established” is reserved for this tier.

Preliminary or emerging. Claims supported by small studies, pilot data, animal or in vitro research, or a limited number of trials. We hedge this tier explicitly, using language like “suggests,” “preliminary evidence indicates,” or “small studies report.” We do not present early-stage findings with the same confidence as established science, regardless of how promising they appear.

Unsupported. Claims with no peer-reviewed evidence, or that contradict established physiology. Rather than repeating these claims uncritically — a common failure mode in supplement and biohacking media — we correct them directly when they’re relevant to a topic we’re covering.

GLP-1, peptide, TRT, and hormonal health content is held to a stricter hedging standard than general wellness content, given the higher stakes of these categories.

A Fourth Category: Real-World and Experiential Reports

Many of the peptides, bioregulators, and small molecules we cover have limited controlled human trial data — the science simply hasn’t caught up to how widely these compounds are already being used. To bridge that gap without overstating what’s actually known, we sometimes include real-world observations from practitioners, long-term users, or our own reviewer’s first-hand experience.

This kind of information is not a fourth evidence tier alongside well-documented, preliminary, and unsupported claims — it isn’t evidence in the clinical sense at all, and we don’t cite it the way we cite a peer-reviewed study. We label it explicitly as experiential (“practitioners and long-term users report…,” “based on first-hand use…”) and keep it visibly separate from cited claims, so readers always know whether they’re looking at what’s been clinically studied or what people are reporting from personal use. Anecdotal and experiential accounts can offer real, practical context that the literature doesn’t yet cover — but they can also be wrong, unrepresentative, or shaped by factors we can’t verify, and we present them with that limitation clearly in view.

How We Handle Off-Label and Investigational Compounds

Many peptides and research compounds covered on this site exist in a regulatory gray zone — not FDA-approved for the uses discussed, sometimes studied only in preclinical or early clinical settings. We disclose this status plainly rather than implying broader approval or clinical adoption than actually exists. Off-label use is described as “studied in relation to” or “used in some clinical contexts for” a given application — never framed as a recommendation. Where a compound’s FDA or legal status is ambiguous or actively evolving, we say so and note the date of that assessment, since these statuses can change.

Sourcing

We prioritize primary sources: peer-reviewed journal articles, clinical trial data from public trial registries, and statements from regulatory bodies such as the FDA. We cite sources inline and link to the original study or a reputable database so readers can verify claims themselves rather than taking our summary on faith.

Content Review

Content on this site is reviewed for accuracy, currency, and practical relevance by Joseph Hall, who brings 8 years of hands-on experience in the peptide, hormone optimization, and GLP-1 industry. He is not a licensed physician, and this review process is a check on industry accuracy and evidence sourcing — not a substitute for the medical evaluation of a licensed healthcare provider, which remains necessary before starting any medication, peptide, or hormone protocol discussed on this site.

We’re transparent about this distinction because it matters: our reviewer brings real, practical familiarity with how these compounds are actually used and discussed in the field, which strengthens our sourcing and framing. It doesn’t substitute for the clinical judgment of a licensed provider evaluating your individual health status, and we don’t present it as though it does.

Corrections Policy

We update articles when evidence changes, when a factual error is identified, or when a compound’s regulatory status shifts. Every article carries a “Last updated” date reflecting the most recent substantive revision. If you believe an article contains an error, contact us and we will review it.

Editorial Independence from Commercial Content

Affiliate and sponsorship relationships do not influence our evidence-tier classifications, our assessment of a compound’s safety or efficacy, or our conclusions in brand and product reviews. Reviews include a “Consider alternatives if” section by policy, specifically to avoid one-sided commercial framing. See our Disclosure page for details on how we handle affiliate relationships.

What We Won’t Publish

• Drug claims for peptides, research chemicals, or off-label compounds
• Specific dosing protocols presented without a “consult a licensed healthcare provider” framing
• Detox or toxin claims without mechanistic support
• Guaranteed-outcome language for any intervention
• Passive-therapy claims framed as equivalent to exercise or medical treatment

Questions or Corrections

If you have a question about our sourcing, evidence classification, or believe you’ve found an error, contact us at info@optimizeforever.com.